|
Medical Diagnosis 2025
艾滋病并发马尔尼菲篮状菌的体外药敏试验分析
|
Abstract:
目的:分析艾滋病(AIDS)合并马尔尼菲篮状菌(TM)感染的体外药敏试验结果及临床治疗效果,为临床合理用药提供依据。方法:收集2016年2月至2018年11月云南省某医院收治的119例AIDS并发TM感染患者的临床病历资料,分析患者的人口学特征、标本类型、TM体外药敏试验结果及临床治疗效果。结果:119例病人中,男性患者是女性的2.61倍。平均年龄为37.08岁,年龄区间3~70岁,以青壮年居多。检出标本类型最多,为血液和骨髓,共105人,占总样本数的88.24%。CD4+T淋巴细胞计数为39 ± 40 cells/μl,大多数患者处于艾滋病晚期。两性霉素B、伊曲康唑和伏立康唑对马尔尼菲篮状菌的敏感性均为100%。119例患者中有8例未接受抗真菌治疗患者均死亡,111例接受了抗真菌治疗,其中105例治疗好转,治疗好转率94.59% (105/111)。两性霉素B治疗组和伏立康唑治疗组好转率比较差异无统计学意义(P = 0.317, χ2 = 0.859)。结论:AIDS合并TM感染好发于CD4+T淋巴细胞计数低于50 cells/μl的患者,临床表现复杂多样。云南省艾滋病并发马尔尼菲篮状菌病推荐选择两性霉素B、伏立康唑和伊曲康唑治疗,尽量避免使用氟康唑和氟胞嘧啶。
Objective: To analyze in vitro drug susceptibility test and clinical treatment effect of AIDS coinfected with Talaromycosis, and to provide the basis for clinical rational drug use. Methods: The clinical medical records of 119 patients infected with both AIDS and Talaromyces marneffei were collected from February 2016 to November 2018 at a hospital in Yunnan province. The demographic characteristics, specimen types, the results of drug susceptibility test in vitro and clinical treatment effect were retrospectively analyzed. Results: Among the 119 patients, men were 2.61 times likely than women. The average age was 37.08 years old, and the age range from 3 to 70 years old. Most of them were young adults. Blood and bone marrow were the most common samples, accounting for 88.24% of the total samples. The mean CD4+T lymphocyte count was 39 ± 40 cells/μl, and most patients are in advanced stages of AIDS. Amphotericin B, Itraconazole and Voriconazole were all 100% sensitive to Talarmoyces marneffei. Among the 119 patients,8 patients who did not receive antifungal therapy all died, and 111 patients who received antifungal therapy, among which 105 patients got better treatment and the treatment improvement rate was 94.59% (105/111). There was no significant difference in improvement rate between amphotericin B treatment group and Voriconazole treatment group (P = 0.317, χ2 = 0.859). Conclusion: A mixed infection of AIDS and T. marneffei develops in patients with a CD4+T lymphocyte count below 50 cells/μl, and its clinical manifestations are complex and diverse. It is recommended to choose amphotericin B, Voriconazole and itraconazole for treatment of AIDS combined with Talaromycosis, and fluconazole and flucytosine shoule be avoided as
[1] | Bordes, C., Leguelinel-Blache, G., Lavigne, J., Mauboussin, J., Laureillard, D., Faure, H., et al. (2020) Interactions between Antiretroviral Therapy and Complementary and Alternative Medicine: A Narrative Review. Clinical Microbiology and Infection, 26, 1161-1170. https://doi.org/10.1016/j.cmi.2020.04.019 |
[2] | Buchacz, K., Armon, C., Palella Jr., F.J., et al. (2020) The HIV Outpatient Study-25 Years of HIV Patient Care and Epidemiologic Research. Open Forum Infectious Diseases, 7, offaa123. |
[3] | Le, T., Wolbers, M., Chi, N.H., Quang, V.M., Chinh, N.T., Huong Lan, N.P., et al. (2011) Epidemiology, Seasonality, and Predictors of Outcome of Aids-Associated Penicillium marneffei Infection in Ho Chi Minh City, Viet Nam. Clinical Infectious Diseases, 52, 945-952. https://doi.org/10.1093/cid/cir028 |
[4] | Joao, I., Bujdáková, H. and Jordao, L. (2020) Opportunist Coinfections by Nontuberculous Mycobacteria and Fungi in Immunocompromised Patients. Antibiotics, 9, Article No. 771. https://doi.org/10.3390/antibiotics9110771 |
[5] | 中华医学会热带病与寄生虫学分会艾滋病学组. 艾滋病合并侵袭性真菌病诊治专家共识[J]. 中华临床感染病杂志, 2019, 12(4): 253-267. |
[6] | Nong, S. and Liang, J. (2013) Bone Marrow Penicillium marneffei Infection in Acquired Immunodeficiency Syndrome Patients: Report of 35 Cases. Tropical Biomedicine, 30, 89-91. |
[7] | 莫让辉, 何祖森, 谢伟雄, 等. AIDS合并播散性马尔尼菲青霉菌病的腹部超声影像学研究[J]. 中国热带医学, 2014, 14(6): 707-710. |
[8] | Ning, C., Lai, J., Wei, W., Zhou, B., Huang, J., Jiang, J., et al. (2018) Accuracy of Rapid Diagnosis of Talaromyces marneffei: A Systematic Review and Meta-Analysis. PLOS ONE, 13, e0195569. https://doi.org/10.1371/journal.pone.0195569 |
[9] | 中华医学会感染病学会艾滋病学组. 艾滋病诊疗指南[J]. 中华传染病杂志, 2006, 24(2): 133-144. |
[10] | AIDS and Hepatitis C Professional Group, Society of Infectious Diseases, Chinese Medical Association Chinese Center for Disease Control and Prevention (2019) Chinese Guidelines for Diagnosis and Treatment of HIV/AIDS (2018 Edition). Electronic Journal of Emerging Infectious Diseases, 4, 65-84. |
[11] | 中华医学会感染病学分会艾滋病丙型肝炎学组, 中国疾病预防控制中心. 中国艾滋病诊疗指南(2018年版) [J]. 新发传染病电子杂志, 2019, 4(2): 65-84. |
[12] | John, T.B., Jonathan, E.K. and Henry, M. (2009) What’s New in the 2009 US Guidelines for the Prevention and Treatment of Opportunistic Infections among Adults and Adolescents with HIV. Topics in HIV Medicine, 17, 109-114. |
[13] | 方丹, 林榕, 徐晓兰. 获得性免疫缺陷综合征患者感染马尔尼菲青霉菌的骨髓检验[J]. 临床检验杂志, 2013, 31(6): 475-476. |
[14] | 陈媛媛, 刘旭辉, 侯明杰, 等. 58例艾滋病合并马尔尼菲青霉菌病病人临床特征分析[J]. 中国艾滋病性病, 2018, 24(1): 30-32, 52. |
[15] | 张云桂, 杨欣平, 李玉叶, 等. 艾滋病合并马尔尼菲篮状菌病82例临床和预后分析[J]. 中国艾滋病性病, 2019, 25(7): 687-690. |
[16] | Hu, Y., Zhang, J., Li, X., Yang, Y., Zhang, Y., Ma, J., et al. (2012) Penicillium marneffei Infection: An Emerging Disease in Mainland China. Mycopathologia, 175, 57-67. https://doi.org/10.1007/s11046-012-9577-0 |
[17] | 李芳, 耿文奎, 邓晓军, 等. 艾滋病合并马尔尼菲青霉菌病患者死亡危险因素分析[J]. 中国临床新医学, 2012, 5(5): 423-427. |
[18] | 张云桂, 高丽, 李惠琴, 等. 不同抗真菌药物对艾滋病合并马尔尼菲篮状菌病临床疗效及体外药敏试验结果分析[J]. 中国皮肤性病学杂志, 2020, 34(5): 555-558. |
[19] | 李凌华, 雷华丽, 唐小平. 我国机会性致病真菌的耐药现状[J]. 国际流行病学传染病学杂志, 2016, 43(6): 412-415. |
[20] | Le, T., Kinh, N.V., Cuc, N.T.K., Tung, N.L.N., Lam, N.T., Thuy, P.T.T., et al. (2017) A Trial of Itraconazole or Amphotericin B for HIV-Associated Talaromycosis. New England Journal of Medicine, 376, 2329-2340. https://doi.org/10.1056/nejmoa1613306 |
[21] | Zeng, W., Qiu, Y., Lu, D., Zhang, J., Zhong, X. and Liu, G. (2015) A Retrospective Analysis of 7 Human Immunodeficiency Virus-Negative Infants Infected by Penicillium marneffei. Medicine, 94, e1439. https://doi.org/10.1097/md.0000000000001439 |
[22] | Ge, Y., Xu, Z., Hu, Y. and Huang, M. (2019) Successful Voriconazole Treatment of Talaromyces marneffei Infection in an HIV-Negative Patient with Osteolytic Lesions. Journal of Infection and Chemotherapy, 25, 204-207. https://doi.org/10.1016/j.jiac.2018.08.007 |
[23] | Liu, D., Liang, L. and Chen, J. (2013) In Vitro Antifungal Drug Susceptibilities of Penicillium marneffei from China. Journal of Infection and Chemotherapy, 19, 776-778. https://doi.org/10.1007/s10156-012-0511-7 |
[24] | 袁锡华, 曹存巍. 伏立康唑与两性霉素B治疗AIDS合并马尔尼菲蓝状菌病的疗效及安全性对比[J]. 广西医科大学学报, 2019, 36(2): 262-265. |